NASDAQ$IART
Integra LifeSciences Holdings Corporation · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Integra LifeSciences' first quarter performance in 2024 reflected a mix of revenue decline and growth across segments, along with updated full-year guidance after the acquisition of Acclarent, Inc
Integra LifeSciences reported first-quarter revenues of $368.9 million, a 3.1% decrease compared to the prior year. GAAP earnings per diluted share were $(0.04), while adjusted earnings per diluted share were $0.55. The company updated its full-year 2024 revenue guidance to $1.672 to $1.687 billion, including the impact of the Acclarent acquisition.
- Revenues declined by 3.1% on a reported basis, with organic revenue down by 2.5% compared to the previous year.
- GAAP earnings per diluted share were $(0.04), while adjusted earnings per diluted share reached $0.55.
- The acquisition of Acclarent, Inc. was completed on April 1, adding approximately $80 million to the full-year revenue guidance.
- Full-year 2024 revenue guidance was updated to a range of $1.672 billion to $1.687 billion.
Headline financials
Revenue & EPS history
Integra LifeSciences · Revenue · Quarterly
$369M
Revenue by segment
Integra LifeSciences · $360M total across 4 segments · Q1 2021
- Neurosurgery$189M+2.3%52.6%
- Wound Reconstruction and Care$88.7M+22.7%24.6%
- Instruments$52M+11.8%14.4%
- Private Label$30.1M+3.4%8.4%
Forward guidance
For the full year 2024, the Company is updating its revenue and adjusted EPS expectations to $1.672 to $1.687 billion and $3.01 to $3.11, respectively. For the second quarter 2024, the Company expects reported revenues in the range of $411 million to $416 million, and adjusted earnings per diluted share are expected to be in the range of $0.60 to $0.65.
Tailwinds
- Revenue range represents reported growth of 8.4% to 9.4%.
- Organic growth of 3.3% to 4.3%.
- Reflects the completion of the Acclarent acquisition.
- Second quarter reported revenues expected in the range of $411 million to $416 million.
- Second quarter adjusted earnings per diluted share are expected to be in the range of $0.60 to $0.65.
Headwinds
- Removal of approximately $10 million of revenue from the relaunch of SurgiMend and PriMatrix beginning in the second half.
- Organic growth for Q2 expected between 1.3% and 2.6%.
- Uncertainties related to global challenges including macroeconomic uncertainties, inflation, and supply chain disruptions.
- Risks associated with the company's ability to execute its operating plan effectively.
- Potential negative impacts from fluctuations in foreign currency exchange rates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-0.2%
Avg return
Earnings day
-1.4%
Avg return
5 days after
-1.8%
Avg return
30 days after
51%
35 / 68 earnings
Positive
+29.2%
Q3 2024
Best reaction
-23.5%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +24.4% | +31.0% | +65.1% | |
| Q4 2025 | -2.1% | -8.9% | -20.6% | |
| Q3 2025 | -23.5% | -26.8% | -15.0% | |
| Q1 2025 | -20.9% | -27.3% | -22.3% | |
| Q4 2024 | +12.1% | +5.3% | -0.2% | |
| Q3 2024 | +29.2% | +28.5% | +25.1% | |
| Q2 2024 | -20.4% | -23.5% | -35.3% | |
| Q1 2024 | -13.2% | -10.0% | +9.9% | |
| Q4 2023 | -16.6% | -18.8% | -19.9% | |
| Q3 2023 | -4.5% | -5.8% | +6.3% | |
| Q2 2023 | -3.1% | -1.1% | -9.5% | |
| Q1 2023 | -6.2% | -5.5% | -34.7% | |
| Q4 2022 | +0.2% | +0.8% | -3.1% | |
| Q3 2022 | +11.1% | +12.7% | +21.1% | |
| Q2 2022 | -1.5% | -0.5% | -14.8% | |
| Q1 2022 | +2.9% | -0.2% | +2.5% | |
| Q4 2021 | +0.9% | +2.6% | -2.8% | |
| Q3 2021 | +7.1% | +7.5% | -5.3% | |
| Q2 2021 | -0.2% | -0.3% | +2.6% | |
| Q1 2021 | -2.0% | -3.4% | -9.9% | |
| Q4 2020 | -4.1% | -2.8% | -6.2% | |
| Q3 2020 | -7.0% | -4.5% | +19.5% | |
| Q2 2020 | +6.4% | +6.6% | -5.6% | |
| Q1 2020 | +1.5% | -2.8% | +7.9% | |
| Q4 2019 | +2.9% | -0.3% | -35.7% | |
| Q3 2019 | -7.7% | -5.1% | -2.0% | |
| Q2 2019 | +12.0% | +14.5% | +8.0% | |
| Q1 2019 | -3.1% | -2.3% | -7.7% | |
| Q4 2018 | +5.7% | +6.1% | +6.5% | |
| Q3 2018 | -12.6% | -13.5% | -13.9% | |
| Q2 2018 | -2.3% | -2.3% | -5.5% | |
| Q1 2018 | +9.8% | +12.7% | +16.7% | |
| Q4 2017 | -4.1% | -4.1% | +0.7% | |
| Q3 2017 | -9.1% | -8.2% | -4.9% | |
| Q2 2017 | -9.9% | -10.7% | -10.9% | |
| Q1 2017 | +4.6% | +5.1% | +12.1% | |
| Q4 2016 | -2.1% | -1.2% | -1.2% | |
| Q3 2016 | +1.6% | -3.4% | +3.8% | |
| Q2 2016 | +6.8% | +6.4% | +9.0% | |
| Q1 2016 | +6.7% | — | — | |
| Q4 2015 | +3.8% | — | — | |
| Q3 2015 | +2.8% | — | — | |
| Q2 2015 | -0.1% | — | — | |
| Q1 2015 | +7.5% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -7.5% | — | — | |
| Q2 2014 | +1.0% | — | — | |
| Q1 2014 | -1.6% | — | — | |
| Q4 2013 | -3.9% | — | — | |
| Q3 2013 | +4.4% | — | — | |
| Q2 2013 | -2.2% | — | — | |
| Q1 2013 | +0.2% | — | — | |
| Q4 2012 | -4.8% | — | — | |
| Q3 2012 | -0.3% | — | — | |
| Q2 2012 | +4.1% | — | — | |
| Q1 2012 | +9.4% | — | — | |
| Q4 2011 | +1.2% | — | — | |
| Q3 2011 | -21.8% | — | — | |
| Q2 2011 | -5.3% | — | — | |
| Q1 2010 | +2.1% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q4 2008 | -0.7% | — | — | |
| Q4 2010 | -0.7% | — | — | |
| Q3 2010 | +2.2% | — | — | |
| Q3 2009 | +2.2% | — | — | |
| Q2 2009 | +6.2% | — | — | |
| Q2 2010 | +6.2% | — | — | |
| Q4 2009 | +6.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro